Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer

Development of a Risk Model Predicting Chemotherapy-induced Grade 3-4 Neutropenia by Paclitaxel/Carboplatin in Epithelial Ovarian Cancer: Prospective Observational Study for Model Development and Retrospective Study for Validation of Developed Model

To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian cancer and to validate this model.

Inclusion Criteria:

• Patients with FIGO stage I-IV epithelial ovarian cancer after staging or debulking surgery
• Patients who is planned to receive (prospective cohort) ro who received (retrospective cohort) adjuvant chemotherapy with paclitaxel and carboplatin
• Patients who have signed approved informed consent

Exclusion Criteria:

• Uncontrolled medical disease
• Active infectious disease
• Previous pelvic radiation therapy
• Previous chemotherapy (prospective cohort)
• Patients with disease which can cause neutropenia
• Patients who will receive other targeted therapy or immunotherapy during adjuvant therapy (prospective cohort).
• Pregnant or lactating woman